Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Afficher le document1. Summary
Ouvrir ce répertoire et afficher son contenu2. Introduction
Ouvrir ce répertoire et afficher son contenu3. Study design and methods
Afficher le document4. Results
Ouvrir ce répertoire et afficher son contenu5. Discussion
Ouvrir ce répertoire et afficher son contenu6. Conclusions and recommendations
Afficher le documentReferences
Fermer ce répertoireAnnexes
Fermer ce répertoireAnnex 1: Detailed results for each drug
Afficher le document1.1 Amoxycillin capsules
Afficher le document1.2 Ampicillin capsules
Afficher le document1.3 Acetylsalicylic acid tablets
Afficher le document1.4 Doxycycline capsules
Afficher le document1.5 Ferrous sulfate tablets
Afficher le document1.6 Phenoxymethylpenicillin tablets
Afficher le document1.7 Tetracycline capsules
Afficher le document1.8 Retinol tablets
Afficher le document1.9 Epinephrine injection
Afficher le document1.10 Ampicillin injection
Afficher le document1.11 Benzylpenicillin injection
Afficher le document1.12 Ergometrine injection
Afficher le document1.13 Procaine penicillin injection
Afficher le documentAnnex 2: Validation of laboratory results
 

1.6 Phenoxymethylpenicillin tablets

SHELF LIFE

Manufacturer A:4 years

ASSAY METHOD

Spectrophotometric method, BP 1988 p. 985. Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

92.5 - 107.5% (BP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

14

100

Harare

2

14

Bulawayo

12

86

Facility samples

   

Total

59

100

Age > 50 % SLife

4

7

Facility type = PCH

44

75

Climate = hot

50

85

Transport = slow

41

89

Longitudinal Series

   

Total

7

100

SUMMARY ASSAY RESULTS

GMS samples

Manufacturer A

Mean age (mths)

 

7.3

Mean assay

 

99.3%

95% CL

96.9-101.7%

No. and % fail

0

0%

Facility samples

Manufacturer A

Mean age (mths)

 

12.5

Mean assay

 

104.0%

95% CL

103.0 - 104.9%

No. and % fail

8

14%

No. and % low fail

0

0%

No, and % high fail

8

14%

Longitudinal series

at Manuf .

at GMS

at facility

Mean age (mths)

 

0

 

8.3

 

16.5

Mean assay

 

100.2%

 

99.2%

 

103.7%

95% CL

99.7-100.7%

96.1- 102.2%

101.9- 105.6%

No, and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

8.2

 

Mean loss (-) or gain (+)

+4.8%

 

95% CL for loss/gain

+.06 to +9.0%


Figure 1 - Results of facility samples

Findings:

a) No expired samples found.

b) All 14 GMS samples were within assay limits (mean 99.3%).

c) Eight of 59 facility samples (14%) failed, all above the upper limit (maximum value 113.9%).

d) No loss of potency was found in seven GMS/facility sample pairs.

e) No initial quality problem was seen.

f) The high values in facility sample potency are not therapeutically significant.

g) No sign of instability, however samples were in the early part of a long shelf-life (mean age 12.5 months, maximum age 33.3 months),

h) Turnover usually fast at facility level (mean storage time 5.4 months, maximum 21.1 months).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013